Compare VRA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | KZIA |
|---|---|---|
| Founded | 1982 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.4M | 100.8M |
| IPO Year | 2010 | 2002 |
| Metric | VRA | KZIA |
|---|---|---|
| Price | $3.26 | $13.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 190.5K | ★ 237.0K |
| Earning Date | 06-10-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $416,097,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $3.24 |
| 52 Week High | $4.39 | $17.40 |
| Indicator | VRA | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 33.22 | 62.22 |
| Support Level | $1.95 | $5.71 |
| Resistance Level | $3.33 | $14.42 |
| Average True Range (ATR) | 0.22 | 1.08 |
| MACD | -0.13 | -0.09 |
| Stochastic Oscillator | 3.42 | 58.33 |
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.